-
Signature
-
/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach
-
Issuer symbol
-
PBYI
-
Transactions as of
-
08 Jul 2025
-
Transactions value $
-
-$166,702
-
Form type
-
4
-
Filing time
-
10 Jul 2025, 20:49:15 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| AUERBACH ALAN H |
President and CEO, Director, 10%+ Owner |
C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES |
/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach |
10 Jul 2025 |
0001358285 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PBYI |
Common Stock |
Sale |
-$90.4K |
-25.6K |
-0.35% |
$3.53 |
7.2M |
08 Jul 2025 |
Direct |
F1 |
| transaction |
PBYI |
Common Stock |
Sale |
-$76.3K |
-21.6K |
-0.3% |
$3.54 |
7.18M |
09 Jul 2025 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: